Best Practices and Emerging Evidence in the Treatment of Atopic Dermatitis in Children and Adolescents
Webcast
0.75 AMA PRA Category 1 Credit™ ...Faculty
OVERVIEW
Best Practices and Emerging Evidence in the Treatment of Atopic Dermatitis in Children and Adolescents is organized by i3 Health.
Dates Available:
December 20, 2024 - December 19, 2025
Statement of Need:
Atopic dermatitis is a chronic, relapsing, inflammatory skin disease that impacts up to 20% of children in the United States (Silverberg et al, 2021). Children with atopic dermatitis experience a high symptom burden, including pruritus, pain, and sleep disturbances, which significantly impact quality of life. Recently, the therapeutic landscape for atopic dermatitis has expanded to include several new options for children (Chu et al, 2024; Davis et al, 2024). Nonsteroidal topicals, topical and oral JAK inhibitors, and anti–IL-4 receptor alpha and anti–IL-13 monoclonal antibodies, are now available to patients. Others, including therapies targeting the OX40 pathway, are under late-stage investigation (Tsuji et al, 2023). As new therapies emerge, it is crucial for members of the interdisciplinary care team to learn about these options that can optimize outcomes for patients. In this activity, Dr. Peter A. Lio, Clinical Assistant Professor of Dermatology & Pediatrics at Northwestern University Feinberg School of Medicine, and Dr. Linda F. Stein Gold, Director of Dermatology Clinical Research and Division Head of Dermatology at Henry Ford Health, provide insights into best practices and emerging evidence in the treatment of atopic dermatitis in children and adolescents.
Learning Objectives:
Upon completion of this activity, participants should be able to
- Appraise clinical features that can inform the differential diagnosis of AD in children and adolescents
- Evaluate the efficacy and safety of novel and emerging therapies for AD in children and adolescents
ACCREDITATION & CREDITS
Jointly Accredited Provider
In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
i3 Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.
Physician Assistants/Associates
i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 12/19/25. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioners
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Nursing Continuing Professional Development
A maximum of 0.75 ANCC contact hours may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.75 ANCC contact hours of pharmacology credit for Advanced Practice Registered Nurses.
Provider approved by the California Board of Registered Nursing, for 0.75 ANCC contact hours.
TARGET AUDIENCE
PhysicianNursingPharmacistPhysician AssistantDermatologistsFamily MedicinePediatriciansNursesHealthcare ProvidersNurse PractitionersSPECIALITIES
DermatologyAllergy and ImmunologyRELATED ONLINE COURSES
Quick Links